A SIRT6 gene therapy trial in senior beagles hit its primary endpoint, lowering biological age and offering a test bed for human medicine.
#longevity# #geroscience# #SIRT6# #genetherapy# #biologicalage#
UniQure said that the benefits of its Huntington’s disease gene therapy drug AMT-130 were not as good after four years as they were after three years in a small trial
$QURE is down ~70% after its Huntington’s gene therapy showed slower disease progression at 48 months but failed to reach statistical significance.
Another function test still looked better but missing data and serious brain inflammation in 17% of high dose patients made the update much harder to trust.